MARKET

BGNE

BGNE

Beigene Ltd
NASDAQ
140.72
-4.22
-2.91%
Opening 11:14 10/05 EDT
OPEN
144.69
PREV CLOSE
144.94
HIGH
144.69
LOW
138.01
VOLUME
19.35K
TURNOVER
2.01M
52 WEEK HIGH
392.30
52 WEEK LOW
118.18
MARKET CAP
14.61B
P/E (TTM)
-6.8916
1D
5D
1M
3M
1Y
5Y
BRIEF-Capital Group Companies Inc's Long Position In H-Shares Of BeiGene Falls To 7.91% - HKEX Filing
BRIEF-Capital Group Companies Inc's Long Position In H-Shares Of BeiGene Falls To 7.91% - HKEX Filing
Reuters · 6h ago
Zymeworks draws bullish view at Wells Fargo ahead of multiple catalysts
Wells Fargo analyst James Shin and the team assumed coverage on cancer-focused biotech Zymeworks Inc. (NYSE:<a href="https://seekingalpha.com/symbol/ZYME?utm_medium=referral&utm_source=webull.com" title="Zymewor...
Seekingalpha · 21h ago
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
Benzinga · 09/20 10:45
BeiGene Says UK's National Institute for Health and Care Excellence Backs Approval of Lymphoma Drug
BeiGene Says UK's National Institute for Health and Care Excellence Backs Approval of Lymphoma Drug
MT Newswires · 09/20 07:30
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technolog...
Business Wire · 09/19 23:01
BeiGene Receives Positive CHMP Opinion For BRUKINSA For The Treatment Of Adults With Marginal Zone Lymphoma
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)))), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today
Benzinga · 09/19 11:12
EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
The European Union drug regulator's human medicines committee has recommended extending the indication for BeiGene's (NASDAQ:<a href="https://seekingalpha.com/symbol/BGNE?utm_medium=referral&utm_source=web...
Seekingalpha · 09/16 13:31
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
Benzinga · 09/12 13:08
More
About BGNE
BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.